Inhibrx Biosciences (INBX) Assets Average (2024 - 2025)
Inhibrx Biosciences' (INBX) quarterly Assets Average came in at $162.0 million in Q4 2025, down 19.68% year-on-year from $201.7 million in Q4 2024, and down 16.85% on a QoQ basis from $194.8 million in Q3 2025.
Inhibrx Biosciences (INBX) Assets Average (2024 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 2 years of Assets Average data on file, last reported at $162.0 million in Q4 2025.
- On a quarterly basis, Assets Average fell 19.68% year-over-year to $162.0 million in Q4 2025; TTM through Dec 2025 was $162.0 million, a 19.68% decrease from a year earlier, with the FY2025 full-year figure at $163.6 million, down 33.03% from the prior year.
- Assets Average for Q4 2025 stood at $162.0 million, down from $194.8 million in the prior quarter.
- Over the last five years, Assets Average for INBX reached as high as $240.5 million in Q3 2024 and fell as low as $162.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 303.40 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 65.01 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.37 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 41.64 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.06 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.71 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.91 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.30 Bn |
| 10 | Inhibrx Biosciences | 1.32 Bn | 1.32 Bn | - | 161.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 161.97 Mn |
| Sep 30, 2025 | 194.79 Mn |
| Jun 30, 2025 | 227.38 Mn |
| Mar 31, 2025 | 211.70 Mn |
| Dec 31, 2024 | 201.66 Mn |
| Sep 30, 2024 | 240.49 Mn |